Scientific Founder, Omid Veiseh, Ph.D., has over a decade of experience developing biotechnologies for clinical application. The transformative research discoveries he made as a postdoctoral research fellow helped catalyze the launch of Sigilon. Through grants from the Juvenile Diabetes Research Foundation and the Department of Defense, Dr. Veiseh worked to develop a bioartificial pancreas for the treatment of patients afflicted with type 1 diabetes. Dr. Veiseh developed a high-throughput pipeline for the synthesis and evaluation of material formulations that are able to resist foreign body reactions. These formulations were used to develop novel biomaterials for enhanced biocompatibility. The results lay the groundwork for encapsulated transplanted cells for delivery of biotherapeutics. In 2017, he will join the faculty at Rice University as an Assistant Professor of Bioengineering. Dr. Veiseh holds a Ph.D. from the University of Washington. He has authored, or co-authored more than 50 peer-reviewed publications and is an inventor on 20 pending or awarded patents.